T2 Biosystems, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Amortization of bond premium
Amortization of operating lease right-of-use assets
Non-cash lease expense
Stock-based compensation expense
Change in fair value of derivative related to Term Loan with related party
Loss on sales of marketable securities
Gain on disposal of property and equipment
Impairment of operating lease asset
Change in fair value of warrant liabilities
Issuance costs related to Common Stock Warrants
Loss on issuance of Series A Redeemable Convertible Preferred Stock and derivative warrant liability
Loss on disposal of property and equipment
Non-cash interest expense to related party
Impairment of property and equipment
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other assets
Inventories
Accounts payable
Accrued expenses and other liabilities
Deferred revenue
Operating lease liabilities

Net cash used in operating activities
Cash flows from investing activities
Purchases of marketable securities
Proceeds from sale of property and equipment
Proceeds from maturities of marketable securities
Proceeds from sales of marketable securities
Purchases and manufacture of property and equipment
Net cash (used in) provided by investing activities

Cash flows from financing activities
Payment of employee restricted stock tax withholdings
Proceeds from issuance of common stock in public offerings, net of offering costs
Proceeds from issuance of shares from employee stock purchase plan and stock option exercises
Principal repayments of finance leases
Proceeds from public offering, net of issuance costs
Proceeds from secondary offering, net of issuance costs
Proceeds from issuance of Series A Redeemable Convertible Preferred Stock and derivative warrant liability
Redemption of Series A redeemable convertible preferred stock
Payment of debt issuance costs to related party
Net cash provided by financing activities

Net change in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosures of cash flow information
Cash paid for interest to related party
Supplemental disclosures of noncash activities
Transfer of T2 owned instruments and components from inventory
Transfer from other liabilities to accrued expenses and other current liabilities
Cashless exercise of Common Stock Warrants
Cancellation of Term Loan in exchange for common stock and Series B Convertible Preferred Stock to related party
Deemed dividend on Series A Redeemable Convertible Preferred Stock
Right-of-use assets obtained in exchange for new operating lease liabilities
Change in fair value of warrants issued and modified
Purchases of property and equipment included in accounts payable and accrued expenses

Reconciliation of cash, cash equivalents and restricted cash at end of period
Cash and cash equivalents
Restricted cash

Comments